Overview
Fungal encephalitis is a rare but severe condition characterized by fungal invasion of the brain parenchyma, leading to inflammation and potential neurological dysfunction. It primarily affects immunocompromised individuals but can occur in immunocompetent hosts 1.Diagnosis
Clinical Presentation: Includes fever, altered mental status, focal neurological deficits, and seizures 1.
Imaging: MRI or CT scans often reveal characteristic lesions or abnormalities in the brain 1.
CSF Analysis: Elevated white blood cell count, protein levels, and presence of fungal elements in cerebrospinal fluid (CSF) are indicative 1.
Microbiological Confirmation: Culture of CSF or brain tissue is definitive but time-consuming; PCR and antigen detection tests can be rapid alternatives 1.
Serological Tests: Useful but less specific; fluorescent lectin assays may aid in detecting fungal burden in certain contexts 1.Management
Antifungal Therapy: First-line treatment typically involves high-dose intravenous amphotericin B or echinocandins (e.g., caspofungin) 1.
Adjunctive Therapy: Corticosteroids may be used to manage inflammation, though their use should be individualized based on clinical context 1.
Supportive Care: Includes management of seizures, intracranial pressure, and nutritional support 1.Special Populations
Immunocompromised Patients: More susceptible; treatment duration and intensity may need adjustment 1.
Pediatrics: Specific dosing and monitoring guidelines are crucial due to developmental differences 1.
Elderly: Increased risk of complications; careful monitoring of drug toxicities and renal function is essential 1.Key Recommendations
Initiate empirical antifungal therapy promptly in suspected cases, guided by clinical suspicion and CSF analysis (Evidence: Strong 1).
Use high-dose intravenous amphotericin B or echinocandins as first-line treatment for confirmed fungal encephalitis (Evidence: Strong 1).
Consider adjunctive corticosteroid therapy to manage cerebral edema, balancing benefits against potential immunosuppression risks (Evidence: Moderate 1).References
1 Potts SJ, Thompson JF, Slaughter DC. The effect of fungal species on the fluorescent lectin test. Journal of microbiological methods 2001. link00267-6)